Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FRLN · as of Mar 31, 2023
Ownership Breakdown
15
Institutional Holders
▼ 1 vs Q4
$16.90M
Total Inst. Value
▼ $1.29M vs Q4
4.36M
Shares Outstanding
freeFloat 614.98%
36.85M
13F Shares Held
▼ 1.20M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FRLN largest shareholders · institutional ownership
Q1 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SYNCONA PORTFOLIO LTD biological products, (no diagnostic substances) | 22.00M | 33.77% | 33.77% | $10.12B | May 12, 2023 | — held |
CHI ADVISORS LLC biological products, (no diagnostic substances) | 4.73M | 7.26% | 7.26% | $2.15B | May 11, 2023 | ▼ 85.0K |
EVENTIDE ASSET MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.70M | 7.22% | 7.22% | $2.16B | May 15, 2023 | ▼ 1.22M |
TFG ASSET MANAGEMENT GP LTD biological products, (no diagnostic substances) | 4.00M | 6.14% | 6.14% | $1.82B | May 15, 2023 | — held |
UBS GROUP AG biological products, (no diagnostic substances) | 500.0K | 76.77% | 76.77% | $227.50M | May 12, 2023 | ▼ 16.9K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 230.6K | 35.41% | 35.41% | $105.00M | May 12, 2023 | ▲ 34.2K |
MORGAN STANLEY biological products, (no diagnostic substances) | 189.5K | 29.10% | 29.10% | $86.23M | May 15, 2023 | ▼ 1.9K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 162.2K | 24.91% | 24.91% | $75.00M | May 15, 2023 | ▲ 135.7K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 116.8K | 17.93% | 17.93% | $53.73M | May 15, 2023 | ▲ 93.0K |
HARBOR CAPITAL ADVISORS, INC. biological products, (no diagnostic substances) | 107.7K | 16.54% | 16.54% | $49.56M | Apr 26, 2023 | ▼ 21.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2023 vs prior quarter
Q1 2023
3
Increased
+262.9K shares1
New Positions
first time holders6
Decreased
−1.34M shares4
Sold Out
fully exitedNet shares change (top 50)
1.08M
+262.9K / −1.34M
Net new holders
-6
1 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FRLN insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Freeline Therapeutics Holdings plc (FRLN) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 514.98%.
The largest institutional shareholder of Freeline Therapeutics Holdings plc is SYNCONA PORTFOLIO LTD, holding approximately 22.00 million shares — equal to 33.77% of outstanding shares — as of March 31, 2023.
A total of 15 institutional investors currently hold FRLN stock, with a combined institutional value of approximately $16,904,846 as of the most recent 13F filing period.
Frequently asked questions
FRLN ownershipFreeline Therapeutics Holdings plc (FRLN) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is SYNCONA PORTFOLIO LTD with a 33.77% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of March 31, 2023.